JPMorgan lifts target for Amneal Pharmaceuticals stock to USD 24.00
Published on 10/24/2026 at 19:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- JPMorgan raised its Amneal Pharmaceuticals target from USD 22.00 to USD 24.00 on October 22, 2026.
- Second-quarter 2026 revenue reached USD 796.20 million, up 9.90 percent year over year.
- Amneal Pharmaceuticals stock costs EUR 18.05 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
- Amneal Pharmaceuticals is scheduled to report third-quarter 2026 results on October 29, 2026.
Amneal Pharmaceuticals (US03168L1052) is trading at EUR 18.05 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. Markets Insider reported on October 22, 2026 that JPMorgan analyst Chris Schott raised the target from USD 22.00 to USD 24.00 and kept an Overweight rating.
Revenue growth sets the baseline
Amneal's second-quarter 2026 revenue reached USD 796.20 million, up 9.90 percent from the same quarter a year earlier. The company also reported adjusted earnings per share of USD 0.30, up 20.00 percent year over year, according to the Yahoo Finance transcript published for the second-quarter report.
The earnings mix was uneven across divisions. Affordable medicines generated USD 490.00 million in second-quarter revenue, up 13.00 percent, while specialty revenue reached USD 149.00 million, up 17.00 percent. AvKARE revenue was USD 157.00 million, down 4.00 percent, according to the same transcript.
How much room does the target imply?
JPMorgan's USD 24.00 target is USD 5.95 above the EUR 18.05 Lang & Schwarz quotation, but the two values use different currencies and are not combined into a percentage. The research action therefore provides a directional valuation reference rather than a direct euro return calculation.
Results date is October 29
Amneal is scheduled to report third-quarter 2026 results on October 29, 2026, with consensus adjusted earnings per share of USD 0.21, according to MetaCap. Its latest published quarter ended June 30, 2026, making the upcoming release the next major test of the growth rate.
Amneal Pharmaceuticals market facts
Amneal Pharmaceuticals market facts
- Company: Amneal Pharmaceuticals, Inc.
- ISIN: US03168L1052
- Ticker: AMRX
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 24, 2026, 1:04 p.m. CEST): EUR 18.05
- Market capitalization: USD 6.5 billion (as of October 23, 2026)
- 52-week range: USD 9.99-21.18 (as of October 23, 2026)
- Price-to-earnings ratio: 41.81 (as of October 23, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Market report S&P 500.
